Yoo‐Joung Ko

1.2k total citations
43 papers, 734 citations indexed

About

Yoo‐Joung Ko is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Yoo‐Joung Ko has authored 43 papers receiving a total of 734 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 15 papers in Surgery. Recurrent topics in Yoo‐Joung Ko's work include Colorectal Cancer Treatments and Studies (13 papers), Pancreatic and Hepatic Oncology Research (11 papers) and Cancer Genomics and Diagnostics (6 papers). Yoo‐Joung Ko is often cited by papers focused on Colorectal Cancer Treatments and Studies (13 papers), Pancreatic and Hepatic Oncology Research (11 papers) and Cancer Genomics and Diagnostics (6 papers). Yoo‐Joung Ko collaborates with scholars based in Canada, United States and France. Yoo‐Joung Ko's co-authors include Kelvin Chan, Scott Berry, Ana Beatriz Kinupe Abrahão, John A. Stewart, Muhammad Zulfiqar, Scot Dowden, Paweł Zalewski, Sharlene Gill, Malcolm J. Moore and Pablo Cano and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and The Lancet Oncology.

In The Last Decade

Yoo‐Joung Ko

40 papers receiving 720 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yoo‐Joung Ko Canada	14	543	269	237	189	117	43	734
Gregory M. Heestand United States	12	351 0.6×	169 0.6×	147 0.6×	231 1.2×	71 0.6×	22	598
Serafina Mammoliti Italy	17	439 0.8×	143 0.5×	157 0.7×	75 0.4×	82 0.7×	50	841
A. Azzedine France	6	733 1.3×	422 1.6×	228 1.0×	214 1.1×	213 1.8×	8	972
Chongqing Tan China	18	632 1.2×	541 2.0×	203 0.9×	104 0.6×	91 0.8×	65	978
Steven J. Nicol United States	14	503 0.9×	337 1.3×	512 2.2×	150 0.8×	161 1.4×	42	1.0k
Isabelle Trouilloud France	13	522 1.0×	269 1.0×	248 1.0×	217 1.1×	205 1.8×	39	689
F. Asrari United States	10	401 0.7×	217 0.8×	173 0.7×	269 1.4×	232 2.0×	23	847
Liubao Peng China	14	471 0.9×	432 1.6×	141 0.6×	73 0.4×	65 0.6×	48	760
Ludovic Evesque France	14	648 1.2×	449 1.7×	447 1.9×	51 0.3×	203 1.7×	57	1.1k
Janice A. Lyons United States	14	399 0.7×	265 1.0×	149 0.6×	298 1.6×	24 0.2×	27	878

Countries citing papers authored by Yoo‐Joung Ko

Since Specialization

Citations

This map shows the geographic impact of Yoo‐Joung Ko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoo‐Joung Ko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoo‐Joung Ko more than expected).

Fields of papers citing papers by Yoo‐Joung Ko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoo‐Joung Ko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoo‐Joung Ko. The network helps show where Yoo‐Joung Ko may publish in the future.

Co-authorship network of co-authors of Yoo‐Joung Ko

This figure shows the co-authorship network connecting the top 25 collaborators of Yoo‐Joung Ko. A scholar is included among the top collaborators of Yoo‐Joung Ko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoo‐Joung Ko. Yoo‐Joung Ko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

MacDonald, Karen V., Gerald Batist, Winson Y. Cheung, et al.. (2025). Patient Preferences for Metastatic Colorectal Cancer Treatment: A Multi-method Approach Using Discrete Choice Experiments and Best–Worst Scaling. Patient. 18(6). 747–761.

Beecroft, J. Robert, Savtaj S. Brar, Xiaolan Feng, et al.. (2024). Pan-Canadian consensus recommendations for GIST management in high- and low-throughput centres across Canada. Therapeutic Advances in Medical Oncology. 16. 12710915–12710915. 1 indexed citations

Kelly, Deirdre, Derek J. Jonker, Yoo‐Joung Ko, et al.. (2022). GATA6 Expression as a predictor of response to perioperative chemotherapy in resectable pancreatic adenocarcinoma: A multicenter Canadian phase II study (NeoPancONE).. Journal of Clinical Oncology. 40(4_suppl). TPS638–TPS638. 9 indexed citations

Isaranuwatchai, Wanrudee, et al.. (2022). Cancer treatment-related financial toxicity experienced by patients in low- and middle-income countries: a scoping review. Supportive Care in Cancer. 30(8). 6463–6471. 19 indexed citations

Renouf, Daniel J., Jonathan M. Loree, Jennifer J. Knox, et al.. (2021). Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).. Journal of Clinical Oncology. 39(3_suppl). 411–411. 7 indexed citations

Thompson, Robert M., Patrick Cheung, William Chu, et al.. (2019). Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: Dose and site of metastases matter. Radiotherapy and Oncology. 142. 236–245. 27 indexed citations

Chan, Kelvin, et al.. (2019). A systematic review and network meta-analysis of adjuvant therapy for curatively resected biliary tract cancers.. Journal of Clinical Oncology. 37(4_suppl). 247–247. 2 indexed citations

Detsky, Jay, Laurent Milot, Yoo‐Joung Ko, et al.. (2018). Perfusion imaging of colorectal liver metastases treated with bevacizumab and stereotactic body radiotherapy. Physics and Imaging in Radiation Oncology. 5. 9–12. 5 indexed citations

Jonker, Derek J., Patricia A. Tang, Hagen F. Kennecke, et al.. (2018). A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial. Clinical Colorectal Cancer. 17(3). 231–239.e7. 47 indexed citations

10.

Coyle, Doug, Yoo‐Joung Ko, Kathryn Coyle, et al.. (2017). Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System. Value in Health. 20(4). 586–592. 17 indexed citations

11.

Abrahão, Ana Beatriz Kinupe, Yoo‐Joung Ko, Scott Berry, & Kelvin Chan. (2017). A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis. Clinical Colorectal Cancer. 17(2). 113–120. 61 indexed citations

12.

Sonpavde, Guru, Gregory R. Pond, Jonathan E. Rosenberg, et al.. (2015). Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology. 33(15_suppl). 4527–4527. 2 indexed citations

13.

Ko, Yoo‐Joung, et al.. (2014). A qualitative study of patient and clinician attitudes regarding surveillance after a resection of pancreatic and periampullary cancer. HPB. 17(5). 409–415. 22 indexed citations

14.

Chan, Kelvin, et al.. (2014). A Bayesian Meta-Analysis of Multiple Treatment Comparisons of Systemic Regimens for Advanced Pancreatic Cancer. PLoS ONE. 9(10). e108749–e108749. 34 indexed citations

15.

Sonpavde, Guru, Joaquim Bellmunt, Jonathan E. Rosenberg, et al.. (2014). Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy.. Journal of Clinical Oncology. 32(4_suppl). 353–353. 2 indexed citations

16.

Lien, Kelly, Scott Berry, Yoo‐Joung Ko, & Kelvin Chan. (2014). The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?. Expert Review of Pharmacoeconomics & Outcomes Research. 15(1). 81–100. 5 indexed citations

17.

Ko, Yoo‐Joung, Som D. Mukherjee, Eric Winquist, et al.. (2013). Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. The Lancet Oncology. 14(8). 769–776. 110 indexed citations

18.

Emmenegger, Urban & Yoo‐Joung Ko. (2013). PSA-based treatment response criteria in castration-resistant prostate cancer: promises and limitations. Canadian Urological Association Journal. 3(5). 375–375. 9 indexed citations

19.

Hird, Amanda, et al.. (2012). Doctor, what are my options? A prospective cohort study of an individualized care plan for patients with gastrointestinal cancer.. Journal of Clinical Oncology. 30(34_suppl). 12–12. 1 indexed citations

20.

Hird, Amanda, Edward Chow, Lisa Ehrlich, et al.. (2008). Rapid Improvement in Pain and Functional Level in a Patient with Metastatic Renal Cell Carcinoma: A Case Report and Review of the Literature. Journal of Palliative Medicine. 11(8). 1156–1161. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact